Exploring the neurobiological mechanisms of ketamine, psychedelics, and other rapid antidepressants

The recent development of novel, fast acting, and durable antidepressant treatments such as Ketamine, Brexanolone, and Psilocybin has disrupted our view of the neuroscience and treatment of mood disorders. Our focus is research into the basic and translational science of how these drugs work.

Anyone interested is welcome to participate!

When: 3rd Monday of the month, 3:00p
Where: HYBRID: Couch Building, room 3001B (Medical Campus) and Zoom
Organizer: Joshua Siegel (Resident, WashU Psychiatry)

Note that individual events are listed on the ONR Calendar.

2023/2024 Schedule

For inquiries contact Joshua Siegel.

September 18, 2023

Joshua Siegel (WashU Psychiatry)

October 16, 2023

Lindsay Cameron (Stanford University)

November 20, 2023

John McCorvy (Medical College of Wisconsin)

December 18, 2023

Boris Heifets (Stanford University)

January 22, 2024

Conor Liston (Cornell University)

February 19, 2024

Eero Castrén (University of Helsinki)

March 18, 2024

Robert Malenka (Stanford University)

April 15, 2024

Rick Strassman (University of New Mexico)

May 20, 2024

Candace Lewis (Arizona State University)

Spring & Summer 2023 Schedule
January 23, 2023

NOTE date

Victoria DeLeon (WashU Psychiatry)

“Ketamine and Nitrous Oxide for Acute Suicidality”

Papers to review:

February 27, 2023

Rescheduled from February 20

Charles Zorumski (WashU Psychiatry)

Topic: New initiative to fund antidepressants research at WashU through the Taylor Foundation

Below are two papers that have just come out that may be of interest to you.

March 20, 2023

Manoj Doss (Johns Hopkins University)

“Cinco Sins of Psychedelic Science”

April 17, 2023

Alex Kwan (Cornell University)

“Visualizing drug actions on dendrites: From ketamine to psilocybin”

May 15, 2023

Charles Conway (WashU Psychiatry)

“A Phase II trial of Nitrous Oxide for TRD”

June 26, 2023

NOTE date

Candace Lewis (Arizona State University)

“Harnessing the malleable epigenome in the pursuit of healing”